Objective: To evaluate the efficacy and toxicity of paclitaxel liposome combined with 5-Fu/CF and DDP in treatment of patients with advanced gastric cancer. Methods:Fifty-six patients with advanced gastric cancer were divided into two groups randomly, the test group and the control group. The test group was treated with paclitaxel liposome 135 mg/m2 on day 1, 5-Fu 500 mg/m2 and CF 200 mg on day 1~5, DDP 20 mg/m2 on day 2~5. The control group was treated with paclitaxel 135 mg/m2 on day 1, 5-Fu 500 mg/m2 and CF 200mg on day 1~5, DDP 20 mg/m2 on day 2~5. The regimen was repeated every 21 days. All patients received at least for 2 cycles. Result: In the test group, the response rate(RR) and the disease controlled rate(DCR) were 46.4%, 78.5% respectively. One-year survival was 39.1%. In the control group, the RR, DCR and one-year survival were 32.1%, 50.0% and 17.8% respectively. The DCR in two groups had significant deviation. About adverse reactions, granulocytopenia, nausea, vomiting and allergy in the test group were decreased significantly compared with the control group. Conclusion: Paclitaxel liposome combined with 5-Fu, CF and DDP is active in patients with advanced gastric cancer and has less toxicity than paclitaxel.